374 related articles for article (PubMed ID: 26101868)
21. RNA sequencing provides novel insights into the pathogenesis of naturally occurring myxomatous mitral valve disease stage B1 in beagle dogs.
Kim TS; Hong CY; Oh SJ; Choe YH; Hwang TS; Kim J; Lee SL; Yoon H; Bok EY; Cho AR; Do YJ; Kim E
PLoS One; 2024; 19(5):e0300813. PubMed ID: 38753730
[TBL] [Abstract][Full Text] [Related]
22. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
Müller S; Menciotti G; Borgarelli M
J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
[TBL] [Abstract][Full Text] [Related]
23. The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease.
Hammond HH; Ames MK; Domenig O; Scansen BA; Yang NT; Wilson MD; Sunshine E; Brunk K; Masters A
J Vet Intern Med; 2023; 37(3):875-886. PubMed ID: 36951394
[TBL] [Abstract][Full Text] [Related]
24. Cardiac troponin-I concentration, myocardial arteriosclerosis, and fibrosis in dogs with congestive heart failure because of myxomatous mitral valve disease.
Falk T; Ljungvall I; Zois NE; Höglund K; Olsen LH; Pedersen HD; Häggström J
J Vet Intern Med; 2013; 27(3):500-6. PubMed ID: 23551840
[TBL] [Abstract][Full Text] [Related]
25. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
Kim HJ; Kim J; Kim S; Kim HJ
BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
[TBL] [Abstract][Full Text] [Related]
26. Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease.
Zhou Q; Cui X; Zhou H; Guo S; Wu Z; Li L; Zhang J; Feng W; Guo Y; Ma X; Chen Y; Qiu C; Xu M; Deng G
BMC Vet Res; 2023 Dec; 19(1):271. PubMed ID: 38087280
[TBL] [Abstract][Full Text] [Related]
27. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
[TBL] [Abstract][Full Text] [Related]
28. QT instability, an indicator of augmented arrhythmogenesis, increases with the progression of myxomatous mitral valve disease in dogs.
Brüler BC; Jojima FS; Dittrich G; Giannico AT; Sousa MG
J Vet Cardiol; 2018 Aug; 20(4):254-266. PubMed ID: 30031743
[TBL] [Abstract][Full Text] [Related]
29. Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.
Kim HS; Kang JH; Jeung EB; Yang MP
J Vet Intern Med; 2016 Sep; 30(5):1589-1600. PubMed ID: 27573621
[TBL] [Abstract][Full Text] [Related]
30. Advances in the understanding of the pathogenesis, progression and diagnosis of myxomatous mitral valve disease in dogs.
Burchell RK; Schoeman J
J S Afr Vet Assoc; 2014 Aug; 85(1):1101. PubMed ID: 25685978
[TBL] [Abstract][Full Text] [Related]
31. Prospective pilot study on the predictive significance of plasma miR-30b-5p through the study of echocardiographic modifications in Cavalier King Charles Spaniels affected by different stages of myxomatous mitral valve disease: The PRIME study.
Ghilardi S; Lecchi C; Bagardi M; Romito G; Colombo FM; Polli M; Franco C; Brambilla PG
PLoS One; 2022; 17(12):e0274724. PubMed ID: 36574372
[TBL] [Abstract][Full Text] [Related]
32. Identification of 2 loci associated with development of myxomatous mitral valve disease in Cavalier King Charles Spaniels.
Madsen MB; Olsen LH; Häggström J; Höglund K; Ljungvall I; Falk T; Wess G; Stephenson H; Dukes-McEwan J; Chetboul V; Gouni V; Proschowsky HF; Cirera S; Karlskov-Mortensen P; Fredholm M
J Hered; 2011; 102 Suppl 1():S62-7. PubMed ID: 21846748
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease.
Borgarelli M; Abbott J; Braz-Ruivo L; Chiavegato D; Crosara S; Lamb K; Ljungvall I; Poggi M; Santilli RA; Haggstrom J
J Vet Intern Med; 2015; 29(2):569-74. PubMed ID: 25818210
[TBL] [Abstract][Full Text] [Related]
34. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
Sudunagunta S; Green D; Christley R; Dukes-McEwan J
J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
[TBL] [Abstract][Full Text] [Related]
35. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of vertebral left atrial size as determined from thoracic radiographs for assessment of left atrial size in dogs with myxomatous mitral valve disease.
Malcolm EL; Visser LC; Phillips KL; Johnson LR
J Am Vet Med Assoc; 2018 Oct; 253(8):1038-1045. PubMed ID: 30272515
[TBL] [Abstract][Full Text] [Related]
37. Genetics of canine myxomatous mitral valve disease.
O'Brien MJ; Beijerink NJ; Wade CM
Anim Genet; 2021 Aug; 52(4):409-421. PubMed ID: 34028063
[TBL] [Abstract][Full Text] [Related]
38. Mitral annular disjunction and myxomatous mitral valve disease in a dog.
Pereira N
J Vet Cardiol; 2024 Feb; 51():9-12. PubMed ID: 37989026
[TBL] [Abstract][Full Text] [Related]
39. Untargeted metabolomic profiling of dogs with myxomatous mitral valve disease and congestive heart failure shows metabolic differences associated with the presence of cardiac cachexia.
Freeman LM; Rush JE; Karlin ET
Am J Vet Res; 2023 Dec; 84(12):. PubMed ID: 38041949
[TBL] [Abstract][Full Text] [Related]
40. Serial measurements of cardiac troponin I in heart failure secondary to canine mitral valve disease.
Chan IP; Wu SY; Chang CC; Chen WY
Vet Rec; 2019 Sep; 185(11):343. PubMed ID: 31439824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
